Last reviewed · How we verify

Advair HFA MDI 115/21 — Competitive Intelligence Brief

Advair HFA MDI 115/21 (Advair HFA MDI 115/21) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Advair HFA MDI 115/21 (Advair HFA MDI 115/21) — Allergy and Asthma Center of El Paso. Advair HFA combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Advair HFA MDI 115/21 TARGET Advair HFA MDI 115/21 Allergy and Asthma Center of El Paso marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Advair 250 Advair 250 Milton S. Hershey Medical Center marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone and salmeterol fluticasone and salmeterol University of Chicago marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbuhaler 160/4.5 Symbicort Turbuhaler 160/4.5 AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
FLIXOTIDE and SERETIDE FLIXOTIDE and SERETIDE GlaxoSmithKline marketed Inhaled corticosteroid (FLIXOTIDE); Inhaled corticosteroid/long-acting beta-2 agonist combination (SERETIDE) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (salmeterol)
Advair HFA Advair HFA University of Colorado, Denver marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
fluticasone/salmeterol in all asthmatics fluticasone/salmeterol in all asthmatics Gelb, Arthur F., M.D. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Advair HFA MDI 115/21 — Competitive Intelligence Brief. https://druglandscape.com/ci/advair-hfa-mdi-115-21. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: